Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PVLA
PVLA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PVLA News
Palvella Therapeutics Q1 2026 Earnings Call Insights
2d ago
seekingalpha
Palvella Therapeutics Reports Q1 Earnings and Financial Position
3d ago
seekingalpha
Palvella Initiates Phase 2 Trial for QTORIN Gel in Angiokeratomas
6d ago
NASDAQ.COM
Palvella Initiates Clinical Trial for Rare Disease Treatment
6d ago
Newsfilter
Palvella Therapeutics to Report Q1 2026 Financial Results
Apr 30 2026
Newsfilter
Palvella Therapeutics Announces Clinical Results Presentation at ISSVA 2026
Apr 20 2026
Newsfilter
Palvella Appoints New Board Member to Drive Rare Disease Innovation
Apr 13 2026
Newsfilter
Palvella Appoints New Senior Vice President of Sales
Apr 07 2026
Newsfilter
Palvella Therapeutics Reports FY Loss and Cash Position
Mar 31 2026
seekingalpha
Palvella Plans NDA Submission for QTORIN™ Rapamycin in 2026
Mar 31 2026
Newsfilter
Review Highlights Treatment Strategies for Lymphatic Malformations
Mar 30 2026
Newsfilter
Palvella Launches QTORIN™ Novel Skin Treatment Drug
Mar 27 2026
Newsfilter
Palvella COO Sells Stock Options Amid Strong Market Surge
Mar 25 2026
Fool
Palvella Executive Sells Shares Amid Positive Developments
Mar 25 2026
NASDAQ.COM
Palvella Therapeutics Director Increases Stake in Public Offering
Mar 24 2026
Fool
Palvella Launches Awareness Campaign for Microcystic Lymphatic Malformations
Mar 10 2026
Newsfilter
Show More News
